Full Press Release Details
Viking Therapeutics Presents New Data on VK5211 Demonstrating Robust Weight Gain in Primates Following 13 Weeks of Treatment.
VKTX
Viking Therapeutics Presents New Data on VK5211 Demonstrating Robust Weight Gain in Primates Following 13 Weeks of Treatment
Key Takeaway: Viking Therapeutics Presents New Data on VK5211 Demonstrating Robust Weight Gain in Primates Following 13 Weeks of Treatment
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+53%
120-day peak, hindsight
Typical move
13.6%
average across 5 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
VK2735
Phase 3 · Weight Loss